12:00 AM
 | 
Dec 18, 2006
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MG98: Development discontinued

MYG said following a strategic review of its cancer pipeline, it and partner MOGN will no longer pursue MG98 and will seek alternative development partners or arrangements for the compound. MG98 has completed the first step...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >